68 related articles for article (PubMed ID: 9815694)
1. Intrapleural injection of brucea javanica oil emulsion provided a long-term benefits in patient with malignant pleural effusion from pleural mesothelioma: A case report.
Zhou H; Wang Q; Jiao L; Bi L; Sang S; Han Y; Gan S; Liu R; A G; Gong Y
Explore (NY); 2024; 20(1):126-129. PubMed ID: 37286465
[TBL] [Abstract][Full Text] [Related]
2. Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC 375101D).
Sasaki Y; Fukuda M; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Yamada K; Kojima A; Nakagawa K
Jpn J Cancer Res; 1990 Feb; 81(2):196-200. PubMed ID: 2110134
[TBL] [Abstract][Full Text] [Related]
3. Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
Ampollini L; Barocelli E; Cavazzoni A; Petronini P; Mucchino C; Cantoni AM; Leonardi F; Ventura L; Barbieri S; Colombo P; Fusari A; Carbognani P; Rusca M; Sonvico F
J Thorac Dis; 2018 Jan; 10(Suppl 2):S207-S220. PubMed ID: 29507788
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease.
Moritz T; Niederle N; Baumann J; May D; Kurschel E; Osieka R; Kempeni J; Schlick E; Schmidt CG
Cancer Immunol Immunother; 1989; 29(2):144-50. PubMed ID: 2720707
[TBL] [Abstract][Full Text] [Related]
5. Effect of combined intrapleural administration of Lactobacillus casei (LC9018) and adriamycin on experimental malignant pleurisy in mice.
Tohgo A; Tanaka NG; Okada H; Osada Y
Jpn J Cancer Res; 1989 Dec; 80(12):1238-45. PubMed ID: 2516851
[TBL] [Abstract][Full Text] [Related]
6. Leveraging the pleural space for anticancer therapies in pleural mesothelioma.
Blyth KG; Adusumilli PS; Astoul P; Darlison L; Lee YCG; Mansfield AS; Marciniak SJ; Maskell N; Panou V; Peikert T; Rahman NM; Zauderer MG; Sterman D; Fennell DA
Lancet Respir Med; 2024 May; ():. PubMed ID: 38740045
[TBL] [Abstract][Full Text] [Related]
7. Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin: curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE).
Hocking AJ; Farrall AL; Newhouse S; Sordillo P; Greco K; Karapetis CS; Dougherty B; Klebe S
BMJ Open; 2021 Mar; 11(3):e047075. PubMed ID: 33782024
[TBL] [Abstract][Full Text] [Related]
8. The Safety and Exploration of the Pharmacokinetics of Intrapleural Liposomal Curcumin.
Hocking A; Tommasi S; Sordillo P; Klebe S
Int J Nanomedicine; 2020; 15():943-952. PubMed ID: 32103948
[TBL] [Abstract][Full Text] [Related]
9. Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection.
Marazioti A; Papadia K; Giannou A; Stathopoulos GT; Antimisiaris SG
Int J Nanomedicine; 2019; 14():3773-3784. PubMed ID: 31213801
[No Abstract] [Full Text] [Related]
10. Nanoparticle formulations of cisplatin for cancer therapy.
Duan X; He C; Kron SJ; Lin W
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Sep; 8(5):776-91. PubMed ID: 26848041
[TBL] [Abstract][Full Text] [Related]
11. Pleural mesothelial cells in pleural and lung diseases.
Batra H; Antony VB
J Thorac Dis; 2015 Jun; 7(6):964-80. PubMed ID: 26150910
[TBL] [Abstract][Full Text] [Related]
12. The pleural mesothelium in development and disease.
Batra H; Antony VB
Front Physiol; 2014; 5():284. PubMed ID: 25136318
[TBL] [Abstract][Full Text] [Related]
13. Nanocarriers for delivery of platinum anticancer drugs.
Oberoi HS; Nukolova NV; Kabanov AV; Bronich TK
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1667-85. PubMed ID: 24113520
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Verschraegen CF; Kumagai S; Davidson R; Feig B; Mansfield P; Lee SJ; Maclean DS; Hu W; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Oct; 129(10):549-55. PubMed ID: 14513369
[TBL] [Abstract][Full Text] [Related]
15. Advances in the management of malignant mesothelioma.
Khalil MY; Mapa M; Shin HJ; Shin DM
Curr Oncol Rep; 2003 Jul; 5(4):334-41. PubMed ID: 12781077
[TBL] [Abstract][Full Text] [Related]
16. Intracavitary therapies for mesothelioma.
Verschraegen CF
Curr Treat Options Oncol; 2001 Oct; 2(5):385-94. PubMed ID: 12057101
[TBL] [Abstract][Full Text] [Related]
17. Liposomal drug formulations. Rationale for development and what we can expect for the future.
Allen TM
Drugs; 1998 Nov; 56(5):747-56. PubMed ID: 9829150
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
